Nagourney Cancer Blog

Patients never have a second chance to receive first-line therapy, yet first-line therapy offers the best chance of durable remission.  

These results confirm that the majority of cancer patients in the US today do not respond to the NCCN guideline therapies that their physici

Your life is too important to rely on statistical averages. Get the personalized approach you deserve.

Biliary tract cancer afflicts 8,000 patients in the US each year. It is separated into intrahepatic and and extrahepatic.

metabolomics are poised to revolutionize breast cancer screening by enhancing diagnostic accuracy and reducing patient discomfort.

I’ve long held that there are no bad cancers, just cancers that we can or cannot treat.

Treatments should really be given more selectively, i.e. “give this chemotherapy only to those people who will benefit from it,” She said.

I received a video from an episode of Americas Got Talent, the popular TV program that features up-and-coming performers.

Genomic findings are a first step. They find targets. The question the patient wants to answer is “Can I hit the target?”

Cancer patients deserve better. Every patient is unique. Their treatment should be as well.

Even here in the potentially curable pancreatic cancer patients, there is a great deal of disagreement on the best treatment.

Nagourney Cancer Institute remains committed to pioneering research and that promise real hope for those affected by pancreatic cancer.